General
Preferred name
MEBENDAZOLE
Synonyms
Vermox ()
Telmin ()
Pantelmin ()
Mebenvet ()
Vermox, Telmin, Pantelmin, Mebenvet ()
NSC-5618 ()
Zhihuanqing ()
Ovitelmin ()
Emverm ()
Ovex ()
Ovochlor ()
Mebendazolum ()
Vermicidin ()
Mebendazol ()
Mebendazole polymorph c ()
CHLORFENSON ()
Orthotran ()
R 17,635 ()
R-17635 ()
NSC-184849 ()
K-6451 ()
Telmintic ()
Mebendazole-d8 ()
P&D ID
PD001898
CAS
31431-39-7
1286787-80-1
Tags
available
drug
Approved by
FDA
First approval
1974
Drug indication
Worm infection
Anthelmintic
Drug Status
approved
vet_approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mebendazole is a long-established broad spectrum anthelmintic drug that is used in human and veterinary medicine. Benzimidazole class compounds like mebendazole interact with the colchicine-binding site of β tubulin and thereby disrupt polymerisation of microtubules. Repurposing of mebendazole for oncological indications has been proposed , with mechanism of action focussing on tubulin depolymerisation .
In 2024 mebendazole was identified as a repurposing candidate with potential to treat the rare genetic disorder autosomal dominant polycystic kidney disease (ADPKD) . Transcriptomic and computational drug discovery tools were used to predict mebendazole's ADPKD potential, and this was validated in vitro (using patient-derived 3D kidney cyst cultures) and in mouse models of the disease. (GtoPdb)
In 2024 mebendazole was identified as a repurposing candidate with potential to treat the rare genetic disorder autosomal dominant polycystic kidney disease (ADPKD) . Transcriptomic and computational drug discovery tools were used to predict mebendazole's ADPKD potential, and this was validated in vitro (using patient-derived 3D kidney cyst cultures) and in mouse models of the disease. (GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
7
Organisms
2
Compound Sets
30
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Pathogen Box
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
51
Molecular Weight
295.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
3
cLogP
2.97
TPSA
84.08
Fraction CSP3
0.06
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
helminthic tubulin polymerization inhibitor
tubulin polymerization inhibitor
Disease
REFERENCE COMPOUNDS
Target
Tubulin
Tubulin ??-1A chain
Tubulin ??-4B chain
TUBA1A, TUBB, TUBB4B
Microtubule/Tubulin
Parasite
Pathway
Cytoskeletal Signaling
Anti-infection
Apoptosis
Cell Cycle/DNA Damage
cytoskeleton
Indication
pinworm, whipworm, hookworm, ascariasis
Therapeutic Class
Antinematodal Agents
Source data
